Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Other Non-Current Assets (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Other Non-Current Assets for 7 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 436.85% year-over-year to $2.8 million, compared with a TTM value of $2.8 million through Dec 2025, up 436.85%, and an annual FY2025 reading of $2.8 million, up 436.85% over the prior year.
  • Other Non-Current Assets was $2.8 million for Q4 2025 at Avidity Biosciences, roughly flat from $2.8 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $2.8 million in Q2 2025 and bottomed at $251000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $980550.0, with a median of $451500.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Assets crashed 49.9% in 2023, then surged 847.46% in 2024.
  • Year by year, Other Non-Current Assets stood at $251000.0 in 2021, then changed by 0.0% to $251000.0 in 2022, then rose by 19.92% to $301000.0 in 2023, then skyrocketed by 73.09% to $521000.0 in 2024, then soared by 436.85% to $2.8 million in 2025.
  • Business Quant data shows Other Non-Current Assets for RNA at $2.8 million in Q4 2025, $2.8 million in Q3 2025, and $2.8 million in Q2 2025.